<DOC>
	<DOCNO>NCT01374087</DOCNO>
	<brief_summary>The primary objective study compare efficacy brachytherapy versus brachytherapy + triptorelin 22.5 mg ( single injection ) subject recurrence prostate cancer previously treat radiotherapy . Efficacy assess biochemical failure-free survival ( BFFS ) curve treatment initiation 5 year . Secondary objective include compare follow : difference time progression subject receive brachytherapy + triptorelin 22.5 mg versus subject receive brachytherapy , BFFS percentages treatment group 5 year treatment initiation , overall survival treatment group , total testosterone change ( baseline visit 12 month ) Prostate Specific Antigen ( PSA ) level ( baseline visit 60 month treatment ) treatment group , quality life ( QoL ) modification ( Spanish version Expanded Prostate Cancer Index Composite ( EPIC ) questionnaire ) baseline score rest measurement , compare safety treatment group .</brief_summary>
	<brief_title>Study Assess Efficacy Brachytherapy With Without Hormone Therapy , Using Triptorelin 22.5mg Patients With Recurrence Prostate Cancer</brief_title>
	<detailed_description>This proof-of-concept , prospective , parallel , multicentre , randomise open-label trial , include follow-up subject conduct 11 centre Spain . Study visit include inclusion visit ( Visit 1 ) , treatment administration visit ( Visit 2 ) , 9 follow-up visit ( Visit 3 Visit 11 ) 3 60 month study treatment administration . All procedure perform visit accordance routine clinical practice . Subjects randomise one two treatment arm ( Group 1 : brachytherapy , Group 2 : brachytherapy + triptorelin 22.5 mg ) . Randomisation stratify accord brachytherapy dose rate ( low high dose rate ) . Visit 1 include collection demographic data , review clinical detail prostate cancer treatment , blood sampling ( Prostate Specific Antigen ( PSA ) , testosterone , haematology biochemistry parameter , appropriate ) , administration QoL questionnaire International Prostatic Symptom Score ( IPSS ) , treatment group allocation . Visit 2 included review eligibility criterion , record concomitant medication adverse event ( AEs ) study drug administration . Visits 3 11 include record AEs concomitant medication , blood sample administration QoL questionnaire IPSS . Following selection visit ( Visit 1 ) , subject schedule brachytherapy . Those subject randomise concomitant hormone therapy group receive single dose triptorelin 22.5 mg intramuscular injection Visit 2 , 2 week follow selection visit ( Visit 1 ) , preferably 2 month receive brachytherapy . One week two week triptorelin administration , subject permit receive anti-androgen counteract transient increase testosterone level . The study prematurely stop due slow enrolment subject . Of planned 86 evaluable subject , 35 screen , 32 randomise 3 November 2011 26 May 2014 . The slow inclusion subject due several factor , among change clinical practice cause subject offer alternative treatment brachytherapy . Due small number subject , none plan efficacy analysis perform . Instead , data analyse follow : - Efficacy data quality life ( QoL ) outcomes displayed listing . - Safety information display use listing summary table .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>1 . A history prostate cancer ( T1T2T3 N0 M0 ) , confirm histopathology initially treat radiotherapy . 2 . Age ≤ 75 year . 3 . Biochemical failure due Phoenix criterion ( nadir + 2 ) local recurrence initial prostate cancer , confirm prostate biopsy , neither regional involvement distant metastasis . 4 . Late local recurrence initial prostate cancer . A recurrence late appear longer 18 month postradiotherapy . 5 . PSA &lt; 10 ng/mL time recurrence . 6 . The subject require amenable brachytherapy treatment . 7 . Adequate urinary function accord questionnaire ( IPSS ≤ 20 point ) . 8 . Suitable bone marrow function , determine : Haemoglobin &gt; 10 g/dL . Neutrophil count &gt; 1.5 x 10^9/L . Platelet count &gt; 100 x 10^9/L . 9 . Suitable liver function determine : serum bilirubin &lt; 1.5 x Upper Normal Level ( UNL ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5xUNL . 10 . Suitable renal function determine : serum creatinine &lt; 1.5 x UNL , creatinine clearance ≥ 60 mL/min . 11 . The subject require ≥ 18 year old . 12 . The subject give write informed consent ( personally sign date ) start studyrelated procedure . 13 . Life expectancy &gt; 5 year . 1 . Evidence metastatic disease . 2 . Previous evidence hormoneresistant cancer . 3 . Lack availability perform regular followup . 4 . Subjects receive receive either luteinizing hormonereleasing hormone ( LHRH ) agonists , antagonist , previous 12 month . 5 . Subjects treatment hormone therapy , include antagonist , megestrol acetate , finasteride , dutasteride , herbaceous product know reduce PSA level , systemic corticosteroid , previous 4 week . 6 . Subjects previously undergone radiotherapy treatment complete within 18 month inclusion . 7 . Subjects preexist heart failure ( New York Heart Association class III IV ) , myocardial infarction within 6 month inclusion . 8 . Subjects significant coexist disease active infection . 9 . Subjects treat investigational therapy within 4 week prior brachytherapy ± triptorelin treatment . 10 . Subjects know hypersensitivity triptorelin , LHRH , LHRHanalogous agonist , excipients triptorelin 22.5 mg. 11 . Subjects mental condition prevent understanding nature , scope potential consequence study , and/or subject show uncooperative attitude .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Recurrent Prostate Carcinoma</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>Triptorelin</keyword>
	<keyword>Hormone Therapy</keyword>
</DOC>